ArticleFrontiers in bioengineering and biotechnology2025
Development of a biomimetic thyroid acellular scaffold as a 3D platform for modeling thyroid cancer aggressiveness and drug resistance.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Application of 3D Cell Culture in Thyroid Cancer.Annals of biomedical engineering · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional two-dimensional (2D) cell culture models for thyroid cancer research fail to recapitulate the complex tumor microenvironment (TME), leading to a significant gap between preclinical findings and clinical outcomes. To address this limitation, this study focuses on the development and characterization of a novel three-dimensional (3D) tumor model utilizing a thyroid acellular scaffold (TAS) derived from rat tissue. We prepared the TAS through an optimized decellularization protocol, followed by comprehensive histological, biochemical, proteomic, and mechanical evaluations. Human thyroid cancer cells were then seeded onto the TAS, and their biological behaviors, including proliferation, invasion, gene expression, and drug sensitivity to cisplatin and vemurafenib, were systematically compared to conventional 2D cultures. Our results demonstrate that the TAS provides a biomimetic microenvironment, successfully preserving the native extracellular matrix (ECM) architecture, key proteins, and a significant fraction of endogenous growth factors. Compared to 2D cultures, cells within the 3D TAS model exhibited significantly enhanced proliferation and time-dependent invasion. Critically, the 3D microenvironment induced a more aggressive phenotype, characterized by upregulated expression of the BRAF V600E oncogene and the induction of epithelial-mesenchymal transition (EMT), and conferred significantly increased resistance to both cisplatin and vemurafenib. These findings indicate that our tissue-specific, TAS-based 3D model successfully recapitulates key pathophysiological hallmarks of thyroid cancer, representing a more clinically relevant and predictive platform for investigating tumor mechanisms and for the preclinical evaluation of novel therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.